Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?
Cumulative evidence supports the use of angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease in patients with and without heart failure. The dose and unique properties of ACE inhibitors, trial data, differences in trial design and demographics, may all contribute to variable responses in clinical outcomes. Pending direct comparator clinical trials between a tissue ACE inhibitor vs a plasma ACE inhibitor, evidence indicates that both ramipril and perindopril can be recommended for secondary risk prevention.
Shah
Apurva D
AD
Division of Cardiovascular Disease and Hypertension, Department of Medicine, Robert Wood Johnson Medical School-UMDNJ, New Brunswick, New Jersey 08903-0019, USA.
Arora
Rohit R
RR
D000293:Adolescent; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D020913:Perindopril / Q000627:therapeutic use; D017257:Ramipril / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D017257:Ramipril; D020913:Perindopril